Pharmacy Disclosure Log 2025

1. Asthma Response 1003
2. Asthma Response 1003 Attachment
3. Biologics - Dermatology Response 1046
4. Biologics Gastro Response 1128
5. Biologics Rheumatology Response 1057
6. Atopic Dermatitis Response 981
7. Biologic Medicines in Gastroenterology Response 847
8. Biologics Rheumatology Response 762
9. Blood Cultures Response 940
10. Curosurf and Peyona Response 1110
11. Dermatology and Respiratory Medicine Response 977
12. Dermatology Response 771
13. Diffuse Large B Cell Lymphoma Response 827
14. Endometrial Cancer Response 923
15. Eosinophilic Oesophagitis (EoE) Response 972
16. Elastomeric Infusion Devices Response 1031
17. Fibrinogen Concentrate, Prothrombin Complex Concentrate, DOAC Antidote, and Blood Products Response 772
18. Fibrinogen Concentrate, Prothrombin Complex Concentrate, DOAC Antidote, and blood Products Response 772 Attachment
19. Formularies and Committees Response 941
20. Friedreich Ataxia Response 921
21. Gastroenterology Response 1156
22. Giant Cell Arteritis Response 1083
23. Human Albumin Response 826
24. Immunoglobulin Treatment Response 932
25. Intra-Vitreal Injections Implants Response 810
26. Intra-vitreal treatments Response 870
27. Intra-Vitreal Injections or Implants Response 1066
28. Intra-Vitreal Treatments Response 1145
29. Lung Cancer Response 1148
30. Lung Cancer Response 864
31. Lung Cancer Response 864 Attachment
32. Medication errors Rocuronium Response 918
33. Melanoma Response 901
34. Migraine Response 856
35. New Biologic and Targeted Medications Response 867
36. Non-Medical uses of Blood Response 802
37. NHS Pharmacy Aseptic Services Response 803
38. Oncology Breast Cancer Response 857
39. Oncology Response 928
40. Ovarian Cancer Response 944
41. Patients treated with Ruxolitinib Response 933
42. Patients treated with Ruxolitinib Response 933 Attachment
43. Primary Diagnosis of GCA Response 784
44. Renal Cell Carcinoma Response 871
45. Renal Cell Carcinoma Response 871 Attachment
46. Spinal Muscular Atrophy Response 794
47. Trust Processes to Reduce Medication Waste Response 885
48. Urothelial Cancer Response 930
49. Wound Formulary Response 860